Stoke Therapeutics, Inc.

NASDAQ:STOK

Biotechnology

Healthcare
$26.69 -1.12%

-$0.34 today

Market cap
$1.75B
Beta
1.19
P/E (TTM)
-11.1
EPS (TTM)
-$2.69
52W Low $11.17High $40.22

Volume 0.76M

Average 0.64M

STOK Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Stoke Therapeutics, Inc.NASDAQ: STOK

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income turns negative

Q1 FY2026 net income was -$50M, compared with $112.88M a year earlier. Trailing-twelve-month net income was -$169.77M. Over 3 fiscal years it compounded at -59.2% a year.

Context

  • Net income amounted to 3.7% of revenue in FY2025, down 239.7 pp from a year earlier.
  • Net income grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 9 analysts of -$231.33M (+3259.9%) for the fiscal year ending Dec 2026, a step up from the -92.3% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$50M-13.7% QoQ
Last fiscal yearDec 2025
-$6.89M-92.3% YoY
LTMMar 2026
-$169.77M-437.7% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-144.3%+131.4%+275.7 pp
1 year-92.3%+3259.9%+3352.1 pp
3-year CAGR-59.2%+204.6%+263.7 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(6.89M) USD
Year-over-year change
+92.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How STOK compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -437.7% is the lowest of 6, against a peer median of +51.2%.
  • Net income amounts to 529.2% of revenue for STOK, versus a peer median of 255.7%.
STOK Competitors
Net Income for STOK and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$546.15M USD+113.1%+12.2%56.9%
WVEWave Life Sciences Ltd.LTM Mar 2026$183.59M USD+63.4%+8.1%255.7%
STOKStoke Therapeutics, Inc.LTM Mar 2026$169.77M USD-437.7%-59.2%529.2%
SLNSilence Therapeutics plcLTM Mar 2026$145.44M USD—+20.7%15782.6%
BEAMBeam Therapeutics Inc.LTM Jun 2026$85.43M USD-78.6%-34.8%54.7%
DSGNDesign Therapeutics, Inc.LTM Mar 2026$69.71M USD+24.0%+3.3%—
PRQRProQR Therapeutics N.V.LTM Mar 2026€45.62M EUR+51.2%-14.2%339.4%
Peer median (excluding STOK) —+51.2%+5.7%255.7%

Competitors are the stored peer set for STOK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(85.81M)(101.07M)(104.7M)(88.98M)(6.89M)
Depreciation & Amortization974K1.55M2.47M2.18M1.77M
Deferred Income Tax172K0000
Stock-Based Compensation16.45M22.85M25.26M27.47M32.24M
Change in Working Capital46K43.02M(6.03M)(28.14M)16.35M
Accounts Receivables0000(4.27M)
Inventory00000
Accounts Payables2.9M121K(3.21M)3.09M21.29M
Other Working Capital(2.85M)42.9M(2.82M)(31.23M)(675K)
Other Non-Cash Items1.26M1.78M1.94M623K2.12M
Operating Cash Flow(66.91M)(31.87M)(81.07M)(86.85M)45.59M
Capital Expenditures(1.2M)(3.96M)(1.62M)(203K)(670K)
Acquisitions (Net)75.23M45.34M000
Purchases of Investments(87.23M)(201.32M)0(167.27M)(322.72M)
Sales of Investments12M159.4M107.56M60M136.58M
Other Investing Activities(75.23M)(45.34M)000
Investing Cash Flow(76.43M)(45.88M)105.95M(107.48M)(186.81M)
Debt Repayment00000
Common Stock Issued1.29M45.34M52.08M128.84M97.39M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(2K)1.07M926K2.25M0
Financing Cash Flow1.28M46.41M53.01M131.09M97.39M
Effect of Forex Changes00000
Net Change in Cash(142.05M)(31.34M)77.89M(63.23M)(43.84M)
Free Cash Flow(68.11M)(35.83M)(82.68M)(87.05M)44.92M

Stoke Therapeutics, Inc.

NASDAQ:STOK

Intrinsic Alpha fair value

Locked

Current Price

$26.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.